GenVivo
Biotechnology company developing in vivo gene-vector immunotherapies for oncology. The organization designs retroviral-based vector platforms (integrating and non-integrating) for systemic delivery of therapeutic genes, maintains in‑house process development and cGMP manufacturing, and conducts preclinical and early-phase clinical programs to advance candidate genetic medicines toward IND and clinical evaluation.
Industries
Nr. of Employees
small (1-50)
Patents
Products
In vivo CAR‑T/NK gene vector for B‑cell malignancies
Systemic vector designed to generate CAR‑expressing T cells and NK cells in patients to target B‑cell cancers.
Dual‑payload immunocytokine vector (IL‑12 + suicide gene) for solid tumors
Vector encoding an immune‑activating cytokine alongside a pro‑drug‑activated suicide gene intended to induce local immune activation and controllable tumor cell killing.
Immunocytokine vector (GM‑CSF + suicide gene) for solid tumors
Vector encoding a myeloid growth factor with a pro‑drug‑activated suicide gene to stimulate anti‑tumor immunity with an incorporated safety mechanism.
GEN-1013
Dual-payload immunocytokine vector carrying Interleukin 12 (IL-12) and proprietary pro-drug facilitated cancer killing gene HSV-eTK for solid tumors.
GEN-310
In vivo CAR-T/NK genetic medicine candidate designed to generate potent T cells and NK cells targeted against B-cell malignancies directly within the patient’s body.
GEN2
Dual-payload immunocytokine vector carrying Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and proprietary pro-drug facilitated cancer killing gene HSV-eTK for solid tumors.
In vivo CAR‑T/NK gene vector for B‑cell malignancies
Systemic vector designed to generate CAR‑expressing T cells and NK cells in patients to target B‑cell cancers.
Dual‑payload immunocytokine vector (IL‑12 + suicide gene) for solid tumors
Vector encoding an immune‑activating cytokine alongside a pro‑drug‑activated suicide gene intended to induce local immune activation and controllable tumor cell killing.
Immunocytokine vector (GM‑CSF + suicide gene) for solid tumors
Vector encoding a myeloid growth factor with a pro‑drug‑activated suicide gene to stimulate anti‑tumor immunity with an incorporated safety mechanism.
GEN-1013
Dual-payload immunocytokine vector carrying Interleukin 12 (IL-12) and proprietary pro-drug facilitated cancer killing gene HSV-eTK for solid tumors.
GEN-310
In vivo CAR-T/NK genetic medicine candidate designed to generate potent T cells and NK cells targeted against B-cell malignancies directly within the patient’s body.
GEN2
Dual-payload immunocytokine vector carrying Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and proprietary pro-drug facilitated cancer killing gene HSV-eTK for solid tumors.
Services
End-to-end in-house manufacturing services including master cell bank creation, drug substance and drug product production, and finished vial packaging for clinical trials.
Process design, optimization, QbD implementation, technical transfer and facility/equipment start-up to enable scalable vector production.
Conduct of in‑house preclinical studies to evaluate safety, toxicology, and anti-tumor efficacy in animal models to support IND-enabling packages.
Protocol development, project management, monitoring, data management, biostatistics, pharmacovigilance, and trial supply management to execute early-phase clinical trials.
Development and qualification of in‑house analytical and cell‑based assays for product release, stability, and investigation support.
End-to-end in-house manufacturing services including master cell bank creation, drug substance and drug product production, and finished vial packaging for clinical trials.
Process design, optimization, QbD implementation, technical transfer and facility/equipment start-up to enable scalable vector production.
Conduct of in‑house preclinical studies to evaluate safety, toxicology, and anti-tumor efficacy in animal models to support IND-enabling packages.
Protocol development, project management, monitoring, data management, biostatistics, pharmacovigilance, and trial supply management to execute early-phase clinical trials.
Development and qualification of in‑house analytical and cell‑based assays for product release, stability, and investigation support.
Expertise Areas
- Gene therapy vector development
- Viral vector biomanufacturing (cGMP)
- Process development and scale-up
- Preclinical safety and efficacy evaluation
Key Technologies
- Retroviral vector platforms (integrating and non‑integrating)
- In vivo CAR vector generation
- Immunocytokine gene delivery
- Suicide gene/pro‑drug systems
News & Updates
Announcement of a leadership appointment to accelerate oncology programs.
Presentation highlighting non‑integrating retroviral vectors that maintain persistent payload expression for gene therapy and vaccinology applications.
Presentation of early clinical and preclinical data for systemic gene vector candidates.
Company announced initiation of patient dosing in a US Phase I/Ib clinical trial evaluating a personalizing systemic gene vector immunotherapy in advanced solid tumors.
Started patient dosing in a Phase I/Ib clinical trial of a systemic gene vector immunotherapy for advanced solid tumors.
Announcement of a leadership appointment to accelerate oncology programs.
Presentation highlighting non‑integrating retroviral vectors that maintain persistent payload expression for gene therapy and vaccinology applications.
Presentation of early clinical and preclinical data for systemic gene vector candidates.
Company announced initiation of patient dosing in a US Phase I/Ib clinical trial evaluating a personalizing systemic gene vector immunotherapy in advanced solid tumors.
Started patient dosing in a Phase I/Ib clinical trial of a systemic gene vector immunotherapy for advanced solid tumors.